Lotus Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.88 M
- Company Age 30 Year, 8 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 3.60 M
- Revenue Growth -10.47%
- Profit Growth 18.49%
- Ebitda 292.71%
- Net Worth -125.70%
- Total Assets -15.32%
About Lotus Drugs
Lotus Drugs Private Limited (LDPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 June 1994 and has a history of 30 years and eight months. Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.88 M.
The company currently has active open charges totaling ₹3.60 M.
Adesh Garg and Jai Garg serve as directors at the Company.
Company Details
-
Location
Ghaziabad, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232UP1994PTC016525
-
Company No.
016525
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Jun 1994
-
Date of AGM
30 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Lotus Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Adesh Garg
|
Managing Director | 07-Jun-1994 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Jai Garg
|
Director | 04-Oct-1999 | Current |
Financial Performance of Lotus Drugs.
Lotus Drugs Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 10.47% decrease. The company also saw a substantial improvement in profitability, with a 18.49% increase in profit. The company's net worth observed a substantial decline by a decrease of 125.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lotus Drugs?
In 2019, Lotus Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.60 M
₹0
Charges Breakdown by Lending Institutions
- Oriental Bank Of Commerce Ltd. : 0.20 Cr
- Oriental Bank Of Commerce : 0.16 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Sep 2003 | Oriental Bank Of Commerce Ltd. | ₹2.00 M | Open |
| 04 Aug 2003 | Oriental Bank Of Commerce | ₹0.95 M | Open |
| 30 May 1998 | Oriental Bank Of Commerce | ₹0.20 M | Open |
| 13 Nov 1995 | Oriental Bank Of Commerce | ₹0.45 M | Open |
How Many Employees Work at Lotus Drugs?
Unlock and access historical data on people associated with Lotus Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lotus Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lotus Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
